[DocSavage87]

I'd focus less on the 70% effective and more on the better dosing regimen, the half then full dose, which is 90% effective.  One can only assume they have sufficient numbers for that approach to hold, and they aren't just throwing that in to help out stock price.  I believe the Oxford profs, who know the data, wouldn't attach their name to such a release, so I think that'll be the true Oxford/AZ offering.  Importantly, even if infected in either dosing regimen, there were no hospitalized or severe cases out of the 131 cases reported.  There is some indication that it could reduce virus transmission.  It's also going to be a lot cheaper, which is important for global efforts, particularly with the reduced dosage requirement.

https://www.ox.ac.uk/news/2020-11-23-oxf...19-vaccine

[DocSavage87]

I'd focus less on the 70% effective and more on the better dosing regimen, the half then full dose, which is 90% effective.  One can only assume they have sufficient numbers for that approach to hold, and they aren't just throwing that in to help out stock price.  I believe the Oxford profs, who know the data, wouldn't attach their name to such a release, so I think that'll be the true Oxford/AZ offering.  Importantly, even if infected in either dosing regimen, there were no hospitalized or severe cases out of the 131 cases reported.  There is some indication that it could reduce virus transmission.  It's also going to be a lot cheaper, which is important for global efforts, particularly with the reduced dosage requirement.

https://www.ox.ac.uk/news/2020-11-23-oxf...19-vaccine